- Entry
- $3.01
- Final
- $2.29 -23.8%
- Target
- —
- Score
- -1.00
AI Brief Summary from the article: BLRX just showed GLIX1 plus olaparib at low doses matched cisplatin in a real patient derived ovarian cancer model. Not cell lines. Actual human tumor tissue. AstraZeneca sells five billion dollars a year of olaparib. It only works in half of ovarian cancer patients. GLIX1 appears to unlock it for the other half.
— ORIGINAL POST ·
BLRX - BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
· r/Shortsqueeze
· Jul 8, 2026